The Mitsubishi Tanabe Pharma Group engages Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) across Europe.

We are committed to ensuring transparency in our interaction with HCPs and HCOs. In accordance with the EFPIA Code of Transfers of Value from Pharmaceutical Companies 2014, details of Transfers of Value made to HCPs and HCOs in Europe by the Mitsubishi Tanabe Pharma Group can be found below. 

The Methodology applied in preparing and collating these figures is available here in both English* and German*.

If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact: 
Finance@mt-pharma-eu.com.

2017 Transfers of Value

Austria
Research & Development €2,978.01
Non-Research & Development €62,180.18
Belgium
Research & Development €5,266.40
Non-Research & Development €3,000.00
Bulgaria
Research & Development €10,503.93
Non-Research & Development €0.00
Croatia
Research & Development €4,818.00
Non-Research & Development €0.00
Cyprus
Research & Development €0.00
Non-Research & Development €0.00
Czech Republic
Research & Development 481,109.30  CZK
Non-Research & Development 0.00 CZK
Denmark
Research & Development €0.00
Non-Research & Development €0.00
Estonia
Research & Development €0.00
Non-Research & Development €0.00
Finland
Research & Development €172,962.67
Non-Research & Development €0.00
France
Research & Development €12,173.26
Non-Research & Development €0.00
Germany
Research & Development €134,280.17
Non-Research & Development €158,139.21
Greece
Research & Development €0.00
Non-Research & Development €1,500.00
Hungary
Research & Development 8,389,766.48 HUF
Non-Research & Development 0.00 HUF
Ireland
Research & Development €0.00
Non-Research & Development €0.00
Italy
Research & Development €165,271.88
Non-Research & Development €8,000.00
Latvia
Research & Development €0.00
Non-Research & Development €0.00
Lithuania
Research & Development €0.00
Non-Research & Development €0.00
Malta
Research & Development €0.00
Non-Research & Development €0.00
The Netherlands
Research & Development €7,495.50
Non-Research & Development €21,643.30
Norway
Research & Development €0.00
Non-Research & Development €0.00
Poland
Research & Development €143,684.74
Non-Research & Development €0.00
Portugal
Research & Development €0.00
Non-Research & Development €0.00
Romania
Research & Development €91.80
Non-Research & Development €0.00
Russia
Research & Development €54,303.49
Non-Research & Development €0.00
Serbia
Research & Development €5,589.50
Non-Research & Development €0.00
Slovakia
Research & Development €9,095.72
Non-Research & Development €0.00
Slovenia
Research & Development €0.00
Non-Research & Development €0.00
Spain
Research & Development €0.00
Non-Research & Development €0.00
Sweden
Research & Development €0.00
Non-Research & Development €0.00
Switzerland
Research & Development €98,455.58
Non-Research & Development €4,163.89
Turkey
Research & Development €61,877.80
Non-Research & Development €0.00
Ukraine
Research & Development €38,379.98
Non-Research & Development €0.00
United Kingdom
Research & Development £616,770.78
Non-Research & Development £66,037.64

 

* The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom and German and therefore disclosure is made according to local requirements for these countries